These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28923231)

  • 21. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients.
    Hernandez-Martinez JM; Sánchez-Reyes R; De la Garza-Salazar JG; Arrieta O
    Adv Exp Med Biol; 2019; 1168():79-90. PubMed ID: 31713165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Surg Oncol Clin N Am; 2020 Jan; 29(1):105-113. PubMed ID: 31757307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision medicine in oncology: what is it exactly and where are we?
    Le Tourneau C; Kamal M; Bièche I
    Per Med; 2018 Sep; 15(5):351-353. PubMed ID: 30260312
    [No Abstract]   [Full Text] [Related]  

  • 25. The Future of Precision Medicine in Oncology.
    Millner LM; Strotman LN
    Clin Lab Med; 2016 Sep; 36(3):557-73. PubMed ID: 27514468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalised cancer medicine.
    Jackson SE; Chester JD
    Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New directions in biomarker research, drug development and personalized medicine].
    Németh G; Jelinek I
    Magy Onkol; 2013 Mar; 57(1):5-10. PubMed ID: 23573515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
    Le Tourneau C; Kamal M; Tsimberidou AM; Bedard P; Pierron G; Callens C; Rouleau E; Vincent-Salomon A; Servant N; Alt M; Rouzier R; Paoletti X; Delattre O; Bièche I
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
    Kotelnikova EA; Pyatnitskiy M; Paleeva A; Kremenetskaya O; Vinogradov D
    Oncotarget; 2016 Aug; 7(32):52493-52516. PubMed ID: 27191992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Future of Precision Oncology for the Treatment of Solid Tumors.
    Klute KA
    Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 35. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.
    MacConaill LE; Lindeman NI; Rollins BJ
    JAMA Oncol; 2015 Oct; 1(7):879-80. PubMed ID: 26181886
    [No Abstract]   [Full Text] [Related]  

  • 36. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision Medicine in Lung Cancer Treatment.
    Shah DR; Masters GA
    Surg Oncol Clin N Am; 2020 Jan; 29(1):15-21. PubMed ID: 31757310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward a More Precise Future for Oncology.
    Murciano-Goroff YR; Taylor BS; Hyman DM; Schram AM
    Cancer Cell; 2020 Apr; 37(4):431-442. PubMed ID: 32289268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision oncology: A new era of cancer clinical trials.
    Renfro LA; An MW; Mandrekar SJ
    Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond.
    Edsjö A; Russnes HG; Lehtiö J; Tamborero D; Hovig E; Stenzinger A; Rosenquist R;
    J Intern Med; 2024 Jun; 295(6):785-803. PubMed ID: 38698538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.